NCT06359730

Brief Summary

Sphincter sparing surgery is oftentimes associated with bowel dysfunction complaints, namely the low anterior resection syndrome (LARS). The LARS questionnaire is widely used to assess this syndrome. With advances in colorectal surgery, sparing sphincter surgeries are gaining popularity. But symptoms after surgery can affect the quality of life which has psychomotor effects. Low anterior resection syndrome score is a worldwide known questionnaire. Many countries have accredited validation and translation of this questionnaire, but to our knowledge; it is the first time in Egypt.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
120

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Dec 2017

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2017

Completed
5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2022

Completed
1.4 years until next milestone

First Submitted

Initial submission to the registry

April 7, 2024

Completed
4 days until next milestone

First Posted

Study publicly available on registry

April 11, 2024

Completed
Last Updated

April 11, 2024

Status Verified

April 1, 2024

Enrollment Period

5 years

First QC Date

April 7, 2024

Last Update Submit

April 7, 2024

Conditions

Keywords

rectal canceranterior resectionLARS

Outcome Measures

Primary Outcomes (11)

  • age

    age of the patients in years was recorded from patient records

    from 2017 to 2022

  • sex

    sex of patients was recorded from patient records

    from 2017 to 2022

  • medical disease

    medical disease like diabetes and hypertension was recorded from patient records

    from 2017 to 2022

  • site of tumor

    tumor site was determined in Cm from anal verge by colonoscopy

    from 2017 to 2022

  • neoadjuvant therapy

    history of neoadjuvant therapy before surgery was obtained from patients records

    from 2017 to 2022

  • site of anastmosis

    site of anastmosis after resection was recorded as colo-rectal or colo-anal

    from 2017 to 2022

  • type of meso-rectal excision

    excision of meso-rectum was recorded if it was partial or complete

    from 2017 to 2022

  • adjuvant therapy

    it was recorded from patients records if he\\she had chemo- or radiotherapy post-operatively

    from 2017 to 2022

  • type of surgery

    from records; surgery was open or laparoscopic

    from 2017 to 2022

  • type of anastmosis

    type of anastmosis(hand sewen or stappled) obtained from records

    from 2017 to 2022

  • LARS score

    obtained by LARS questionnaire filled by the patient during follow up, it was formed of five questions with different scores on answer choices, interpretaion (0-20) means no LARS, (21- 29) means minor LARS, (30-42) means major LARS

    from 2017 to 2022

Interventions

LARS score questionnaire is filled by the patient after anterior resection for rectal cancer to study the quality of life

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)
Sampling MethodProbability Sample
Study Population

patients who had anterior resection surgery for rectal carcinoma

You may qualify if:

  • Age more than 18
  • Diagnosed patients with rectal adenocarcinoma and who received low anterior resection with anastomosis creation or after a minimum 6 months interval after stoma reversal.
  • Tumors of the rectum (2-15 cm) from anal verge

You may not qualify if:

  • cognitive dysfunction
  • Having a history of inflammatory bowel disease or any disease with bowel function impairment namely, Crohn's disease, irritable bowel syndrome, ulcerative colitis or others.
  • Age less than 18
  • Metastatic cancer or tumor recurrence
  • Rectal tumors within 2 cm from anal verge( abdominoperineal)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Zagazig University Hospitals

Zagazig, 44519, Egypt

Location

MeSH Terms

Conditions

Colorectal NeoplasmsRectal Neoplasms

Condition Hierarchy (Ancestors)

Intestinal NeoplasmsGastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesGastrointestinal DiseasesColonic DiseasesIntestinal DiseasesRectal Diseases

Study Officials

  • Reham Zakaria, PhD

    faculty of medicine Zagazig University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER GOV
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

April 7, 2024

First Posted

April 11, 2024

Study Start

December 1, 2017

Primary Completion

December 1, 2022

Study Completion

December 1, 2022

Last Updated

April 11, 2024

Record last verified: 2024-04

Data Sharing

IPD Sharing
Will not share

IPD will be shared with other researchers on demand by e- mailing the principle investigator

Locations